Ohmyungsamycin promotes M1-like inflammatory responses to enhance host defence against Mycobacteroides abscessus infections

References

• Cruz-Aguilar M, Castillo-Rodal AI, Arredondo-Hernandez R, et al. Non-tuberculous mycobacteria immunopathogenesis: closer than they appear. A prime of innate immunity trade-off and NTM ways into virulence. Scand J Immunol. 2021;94(2):e13035. DOI:10.1111/sji.13035
   PubMed Web of Science ®Google Scholar
• Honda JR, Alper S, Bai X, et al. Acquired and genetic host susceptibility factors and microbial pathogenic factors that predispose to nontuberculous mycobacterial infections. Curr Opin Immunol. 2018;54:66–73. DOI:10.1016/j.coi.2018.06.001
   PubMed Web of Science ®Google Scholar
• Thornton CS, Mellett M, Jarand J, et al. The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health. Eur Respir Rev. 2021;30(160):200299. DOI:10.1183/16000617.0299-2020
   PubMed Web of Science ®Google Scholar
• Tran T, Bonham AJ, Chan ED, et al. A paucity of knowledge regarding nontuberculous mycobacterial lipids compared to the tubercle bacillus. Tuberculosis (Edinb). 2019;115:96–107. DOI:10.1016/j.tube.2019.02.008
   PubMed Web of Science ®Google Scholar
• Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016;354(6313):751–757. DOI:10.1126/science.aaf8156
   PubMed Web of Science ®Google Scholar
• Turenne CY. Nontuberculous mycobacteria: insights on taxonomy and evolution. Infect Genet Evol. 2019;72:159–168. DOI:10.1016/j.meegid.2019.01.017
   PubMed Web of Science ®Google Scholar
• Shrivastava K, Kumar C, Singh A, et al. An overview of pulmonary infections due to rapidly growing mycobacteria in South Asia and impressions from a subtropical region. Int J Mycobacteriol. 2020;9(1):62–70. DOI:10.4103/ijmy.ijmy_179_19
   PubMed Web of Science ®Google Scholar
• Honda JR, Virdi R, Chan ED. Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches. Front Microbiol. 2018;9:2029. DOI:10.3389/fmicb.2018.02029
   PubMed Web of Science ®Google Scholar
• Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis. 2011;17(3):343–349. DOI:10.3201/eid170310060
   PubMed Web of Science ®Google Scholar
• Victoria L, Gupta A, Gomez JL, et al. Mycobacterium abscessus complex: a review of recent developments in an emerging pathogen. Front Cell Infect Microbiol. 2021;11:659997. DOI:10.3389/fcimb.2021.659997
   PubMed Web of Science ®Google Scholar
• Tortoli E, Kohl TA, Brown-Elliott BA, et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol. 2016;66(11):4471–4479. DOI:10.1099/ijsem.0.001376
   PubMedGoogle Scholar
• Strnad L, Winthrop KL. Treatment of Mycobacterium abscessus complex. Semin Respir Crit Care Med. 2018;39(03):362–376. DOI:10.1055/s-0038-1651494
   PubMedGoogle Scholar
• Prasla Z, Sutliff RL, Sadikot RT. Macrophage signaling pathways in pulmonary nontuberculous mycobacteria infections. Am J Respir Cell Mol Biol. 2020;63(2):144–151. DOI:10.1165/rcmb.2019-0241TR
   PubMed Web of Science ®Google Scholar
• Shin DM, Yang CS, Yuk JM, et al. Mycobacterium abscessus activates the macrophage innate immune response via a physical and functional interaction between TLR2 and dectin-1. Cell Microbiol. 2008;10(8):1608–1621. DOI:10.1111/j.1462-5822.2008.01151.x
   PubMed Web of Science ®Google Scholar
• Shamaei M, Mirsaeidi M, Richardson AR. Nontuberculous mycobacteria, macrophages, and host innate immune response. Infect Immun. 2021;89(8):e0081220. DOI:10.1128/IAI.00812-20
   PubMed Web of Science ®Google Scholar
• Yoo JW, Jo KW, Kang BH, et al. Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy. Eur Respir J. 2014;44(5):1289–1295. DOI:10.1183/09031936.00063514
   PubMed Web of Science ®Google Scholar
• Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70(7):677–682. DOI:10.1136/thoraxjnl-2014-206470
   PubMed Web of Science ®Google Scholar
• Hase I, Morimoto K, Sakagami T, et al. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review. Diagn Microbiol Infect Dis. 2017;88(4):308–315. DOI:10.1016/j.diagmicrobio.2017.05.011
   PubMed Web of Science ®Google Scholar
• Lai HC, Chang CJ, Lin CS, et al. NK Cell–derived IFN-γ protects against nontuberculous mycobacterial lung infection. J Immunol. 2018;201(5):1478–1490. DOI:10.4049/jimmunol.1800123
   PubMed Web of Science ®Google Scholar
• Wang X, Chen S, Ren H, et al. HMGN2 regulates non-tuberculous mycobacteria survival via modulation of M1 macrophage polarization. J Cell Mol Med. 2019;23(12):7985–7998. DOI:10.1111/jcmm.14599
   PubMed Web of Science ®Google Scholar
• Um S, Choi TJ, Kim H, et al. Ohmyungsamycins A and B: cytotoxic and antimicrobial cyclic peptides produced by Streptomyces sp. from a volcanic island. J Org Chem. 2013;78(24):12321–12329. DOI:10.1021/jo401974g
   PubMed Web of Science ®Google Scholar
• Kim TS, Shin YH, Lee HM, et al. Ohmyungsamycins promote antimicrobial responses through autophagy activation via AMP-activated protein kinase pathway. Sci Rep. 2017;7(1):3431. DOI:10.1038/s41598-017-03477-3
   PubMedGoogle Scholar
• Wolf NM, Lee H, Zagal D, et al. Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions. Acta Crystallogr D Struct Biol. 2020;76(5):458–471. DOI:10.1107/S2059798320004027
   PubMedGoogle Scholar
• Hosoda K, Koyama N, Hamamoto H, et al. Evaluation of anti-mycobacterial compounds in a silkworm infection model with Mycobacteroides abscessus. Molecules. 2020;25(21):4971. DOI:10.3390/molecules25214971
   PubMed Web of Science ®Google Scholar
• Byun WS, Kim S, Shin YH, et al. Antitumor activity of ohmyungsamycin a through the regulation of the Skp2-p27 Axis and MCM4 in human colorectal cancer cells. J Nat Prod. 2020;83(1):118–126. DOI:10.1021/acs.jnatprod.9b00918
   PubMed Web of Science ®Google Scholar
• Kim E, Du YE, Ban YH, et al. Enhanced ohmyungsamycin a production via adenylation domain engineering and optimization of culture conditions. Front Microbiol. 2021;12:626881. DOI:10.3389/fmicb.2021.626881
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lee SH, Jeon SM, et al. Sirtuin 3 is essential for host defense against Mycobacterium abscessus infection through regulation of mitochondrial homeostasis. Virulence. 2020;11(1):1225–1239. DOI:10.1080/21505594.2020.1809961
   PubMed Web of Science ®Google Scholar
• Silwal P, Kim JK, Jeon SM, et al. Mitofusin-2 boosts innate immunity through the maintenance of aerobic glycolysis and activation of xenophagy in mice. Commun Biol. 2021;4(1):548. DOI:10.1038/s42003-021-02073-6
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lee JY, Lee JJ, et al. Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous Mycobacterial infection. Gut Microbes. 2022;14(1):2073132. DOI:10.1080/19490976.2022.2073132
   PubMed Web of Science ®Google Scholar
• Kim TS, Choe JH, Kim YJ, et al. Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017;61(9):61. DOI:10.1128/AAC.02752-16
   Web of Science ®Google Scholar
• Bich Hanh BT, Quang NT, Park Y, et al. Omadacycline potentiates clarithromycin activity against Mycobacterium abscessus. Front Pharmacol. 2021;12:790767. DOI:10.3389/fphar.2021.790767
   PubMed Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. DOI:10.1093/jac/dkg301
   PubMed Web of Science ®Google Scholar
• Le Moigne V, Raynaud C, Moreau F, et al. Efficacy of bedaquiline, alone or in combination with imipenem, against Mycobacterium abscessus in C3HeB/FeJ mice. Antimicrob Agents Chemother. 2020;64(6):64. DOI:10.1128/AAC.00114-20
   Web of Science ®Google Scholar
• Orecchioni M, Ghosheh Y, Pramod AB, et al. Corrigendum: macrophage polarization: different gene signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively activated macrophages. Front Immunol. 2020;11:234. DOI:10.3389/fimmu.2019.01084
   PubMed Web of Science ®Google Scholar
• Ghafourifar P, Parihar MS, Nazarewicz R, et al. Detection assays for determination of mitochondrial nitric oxide synthase activity; advantages and limitations. Methods Enzymol. 2008;440:317–334. DOI:10.1016/S0076-6879(07)00821-X
   PubMed Web of Science ®Google Scholar
• Patoli D, Mignotte F, Deckert V, et al. Inhibition of mitophagy drives macrophage activation and antibacterial defense during sepsis. J Clin Invest. 2020;130(11):5858–5874. DOI:10.1172/JCI130996
   PubMed Web of Science ®Google Scholar
• Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med. 2011;208(3):519–533. DOI:10.1084/jem.20102049
   PubMed Web of Science ®Google Scholar
• Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A. 2000;97(16):8841–8848. DOI:10.1073/pnas.97.16.8841
   PubMed Web of Science ®Google Scholar
• Braga LC, Leite AA, Xavier KG, et al. Synergic interaction between pomegranate extract and antibiotics against Staphylococcus aureus. Can J Microbiol. 2005;51(7):541–547. DOI:10.1139/w05-022
   PubMed Web of Science ®Google Scholar
• Kragh KN, Gijon D, Maruri A, et al. Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening. J Antimicrob Chemother. 2021;76(4):1001–1009. DOI:10.1093/jac/dkaa543
   PubMed Web of Science ®Google Scholar
• Kim E, Shin YH, Kim TH, et al. Characterization of the ohmyungsamycin biosynthetic pathway and generation of derivatives with improved antituberculosis activity. Biomolecules. 2019;9(11):672. DOI:10.3390/biom9110672
   PubMed Web of Science ®Google Scholar
• Bernut A, Herrmann JL, Ordway D, et al. The diverse cellular and animal models to decipher the physiopathological traits of Mycobacterium abscessus infection. Front Cell Infect Microbiol. 2017;7:100. DOI:10.3389/fcimb.2017.00100
   PubMed Web of Science ®Google Scholar
• Rosenthal IM, Tasneen R, Peloquin CA, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012;56(8):4331–4340. DOI:10.1128/AAC.00912-12
   PubMed Web of Science ®Google Scholar
• Lanoix JP, Lenaerts AJ, Nuermberger EL. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech. 2015;8(6):603–610. DOI:10.1242/dmm.019513
   PubMed Web of Science ®Google Scholar
• Irwin SM, Driver E, Lyon E, et al. Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. Dis Model Mech. 2015;8(6):591–602. DOI:10.1242/dmm.019570
   PubMed Web of Science ®Google Scholar
• Driver ER, Ryan GJ, Hoff DR, et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(6):3181–3195. DOI:10.1128/AAC.00217-12
   PubMed Web of Science ®Google Scholar
• Bertolini TB, de Souza AI, Gembre AF, et al. Genetic background affects the expansion of macrophage subsets in the lungs of Mycobacterium tuberculosis-infected hosts. Immunology. 2016;148:102–113. DOI:10.1111/imm.12591
   PubMed Web of Science ®Google Scholar
• Maggioncalda EC, Story-Roller E, Mylius J, et al. A mouse model of pulmonary Mycobacteroides abscessus infection. Sci Rep. 2020;10(1):3690. DOI:10.1038/s41598-020-60452-1
   PubMed Web of Science ®Google Scholar
• MacMicking JD, North RJ, LaCourse R, et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A. 1997;94(10):5243–5248. DOI:10.1073/pnas.94.10.5243
   PubMed Web of Science ®Google Scholar
• Okamoto S. Hematopoietic stem cell transplantation for lymphoma. Nihon Rinsho. 2007;65:563–568. Suppl 1. PMID:17474463
   PubMedGoogle Scholar
• Lee JY, Lee MS, Kim DJ, et al. Nucleotide-binding oligomerization domain 2 contributes to limiting growth of Mycobacterium abscessus in the lung of mice by regulating cytokines and nitric oxide production. Front Immunol. 2017;8:1477. DOI:10.3389/fimmu.2017.01477
   PubMed Web of Science ®Google Scholar
• Ahn JH, Park JY, Kim DY, et al. Type I interferons are involved in the intracellular growth control of Mycobacterium abscessus by mediating NOD2-induced production of nitric oxide in macrophages. Front Immunol. 2021;12:738070. DOI:10.3389/fimmu.2021.738070
   PubMed Web of Science ®Google Scholar
• Mohareer K, Medikonda J, Vadankula GR, et al. Mycobacterial control of host mitochondria: bioenergetic and Metabolic changes shaping cell fate and infection outcome. Front Cell Infect Microbiol. 2020;10:457. DOI:10.3389/fcimb.2020.00457
   PubMed Web of Science ®Google Scholar
• Kim TS, Jin YB, Kim YS, et al. SIRT3 promotes antimycobacterial defenses by coordinating mitochondrial and autophagic functions. Autophagy. 2019;15(8):1356–1375. DOI:10.1080/15548627.2019.1582743
   PubMed Web of Science ®Google Scholar
• Kim BR, Kim BJ, Kook YH, et al. Mycobacterium abscessus infection leads to enhanced production of type 1 interferon and NLRP3 inflammasome activation in murine macrophages via mitochondrial oxidative stress. PLoS Pathog. 2020;16(3):e1008294. DOI:10.1371/journal.ppat.1008294
   PubMed Web of Science ®Google Scholar
• Zahrt TC, Deretic V. Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid Redox Signal. 2002;4(1):141–159. DOI:10.1089/152308602753625924
   PubMed Web of Science ®Google Scholar
• Ehrt S, Schnappinger D. Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol. 2009;11(8):1170–1178. DOI:10.1111/j.1462-5822.2009.01335.x
   PubMed Web of Science ®Google Scholar
• Ferrari CK, Souto PC, Franca EL, et al. Oxidative and nitrosative stress on phagocytes’ function: from effective defense to immunity evasion mechanisms. Arch Immunol Ther Exp (Warsz). 2011;59(6):441–448. DOI:10.1007/s00005-011-0144-z
   PubMed Web of Science ®Google Scholar
• Billack B. Macrophage activation: role of toll-like receptors, nitric oxide, and nuclear factor kappa B. Am J Pharm Educ. 2006;70(5):102. DOI:10.5688/aj7005102
   PubMed Web of Science ®Google Scholar
• Santoriello C, Zon LH. Modeling human disease in zebrafish. J Clin Invest. 2012;122(7):2337–2343. DOI:10.1172/JCI60434
   PubMed Web of Science ®Google Scholar
• Howe K, Clark MD, Torroja CF, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013;496(7446):498–503. DOI:10.1038/nature12111
   PubMed Web of Science ®Google Scholar
• Sullivan JR, Lupien A, Kalthoff E, et al. Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline. PLoS Pathog. 2021;17(10):e1009965. DOI:10.1371/journal.ppat.1009965
   PubMed Web of Science ®Google Scholar
• Nie WJ, Xie ZY, Gao S, et al. Efficacy of moxifloxacin against Mycobacterium abscessus in zebrafish model in vivo. Biomed Environ Sci. 2020;33(5):350–358. DOI:10.3967/bes2020.047
   PubMed Web of Science ®Google Scholar
• Hanh BTB, Kim TH, Park JW, et al. Etamycin as a novel Mycobacterium abscessus inhibitor. Int J Mol Sci. 2020;21(18):21. DOI:10.3390/ijms21186908
   Google Scholar
• Bernut A, Le Moigne V, Lesne T, et al. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. Antimicrob Agents Chemother. 2014;58(7):4054–4063. DOI:10.1128/AAC.00142-14
   PubMed Web of Science ®Google Scholar
• Ramis IB, Figueiredo R, Ramos DF, et al. Activity of rifabutin and hemi-synthetic derivatives against Mycobacterium abscessus. Med Chem. 2018;14(4):394–399. DOI:10.2174/1573406414666171204102633
   PubMed Web of Science ®Google Scholar
• Meir M, Barkan D. Alternative and experimental therapies of Mycobacterium abscessus infections. Int J Mol Sci. 2020;21(18):6793. DOI:10.3390/ijms21186793
   PubMed Web of Science ®Google Scholar
• Johansen MD, Daher W, Roquet-Baneres F, et al. Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus. Antimicrob Agents Chemother. 2020;64(11):64. DOI:10.1128/AAC.00363-20
   Web of Science ®Google Scholar